Stereotactic Radiosurgery in Treating Patients with Small Cell Cancer and 1-10 Brain Metastases
- Participants must have a biopsy-proven tumor consistent with small cell lung cancer, or small cell cancer of any primary site, and intracranial lesions radiographically consistent with or pathologically proven to be brain metastases; patients who have undergone prior systemic therapy are eligible
- 1-10 definitive intracranial lesions must be present on magnetic resonance imaging (MRI) of the brain
- Participants who have undergone prior radiation for brain metastases; patients who have undergone resection of one or more brain metastases but who have not yet started adjuvant radiotherapy are eligible for the study
- Participants who have received prophylactic cranial radiation for prevention of brain metastases
- Participants who cannot receive gadolinium
- Participants with stage IV-V chronic kidney disease or end stage renal disease
- Participants with widespread, definitive leptomeningeal disease
- Participants with a maximum tumor diameter exceeding 5 cm (if not resected)
- Participants with > 10 definitive lesions consistent with brain metastases; lesions 2 mm or less in maximum unidimensional size or less may not be included in the total count at the discretion of the radiation oncologist
- Participants with inadequate mental capacity to complete quality of life questionnaires
I. To test the hypothesis that, among patients with small cell lung cancer (SCLC) or small cell cancer of any primary and 1-10 brain metastases, use of stereotactic radiation will not result in a worse rate of neurologic death than historical controls managed with whole-brain radiation therapy (WBRT).
I. All-cause mortality.
II. Quality of life.
III. Neurocognitive function.
IV. Ability to complete activities of daily living.
V. Performance status.
VI. Incidence and time to detection of new brain metastases.
VII. Incidence and time to local recurrence of existing brain metastases.
VIII. Incidence and time to development of radiation necrosis.
IX. Incidence and time to development of leptomeningeal disease.
X. Incidence and time to progressive intracranial disease.
XI. Incidence and time to salvage craniotomy.
XII. Incidence and time to additional central nervous system (CNS)-directed radiotherapeutic treatments (stereotactic or WBRT) after the initial course.
XIII. Incidence and time to the development of seizures.
Patients with lesions < 3 cm in maximum diameter undergo 1 fraction of stereotactic radiosurgery over 30-60 minutes, and patients with lesions > 3 cm in maximum diameter undergo stereotactic radiosurgery over 30-60 minutes once daily on days 1-5 for 5 fractions.
After completion of study treatment, patients are followed up every 2-3 months.
Trial Phase Phase II
Trial Type Treatment
Dana-Farber Harvard Cancer Center
Ayal Aaron Aizer
- Primary ID 17-550
- Secondary IDs NCI-2018-00391
- Clinicaltrials.gov ID NCT03391362